Our quantitative data points are meant to provide a high-level understanding of factors in equity risk models for Natus Medical Inc. Portfolio managers use these models to forecast risk, optimize portfolios and review performance.
We show how NTUS stock compares to 2,000+ US-based stocks, and to peers in the Health Technology sector and Medical Specialties industry.
Please do not consider this data as investment advice. Data is downloaded from sources we deem reliable, but errors may occur.
Natus Medical, Inc. provides medical device solutions focuses on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages. Its products are used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, sleep disorders, neuromuscular diseases and balance and mobility disorders. The company was founded by Maurizio Liverani, John Robert Camber Porter, William New, Jr., Brian Prinn and William W. Moore on May 26, 1987 and is headquartered in Pleasanton, CA.
Many of the following risk metrics are standardized and transformed into quantitative factors in institutional-level risk models.
Rankings below represent percentiles from 1 to 100, with 1 being the lowest rating of risk.
Stocks with higher beta exhibit higher sensitivity to the ups and downs in the market. (↑↑)
Stocks with higher market capitalization often have lower risk. (↑↓)
Higher average daily dollar volume over the past 30 days implies lower liquidity risk. (↑↓)
Higher price momentum stocks, aka recent winners, equate to lower risk for many investors. (↑↓)
Style risk factors often include measures of profitability and payout levels.
Companies with higher earnings generally provide lower risk. (↑↓)
Companies with higher dividend yields, if sustaintable, are perceived to have lower risk. (↑↓)